SEC Form 4 · accession 0001209191-19-018232
IRONWOOD PHARMACEUTICALS INC · IRWD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark G Currie
Officer — Chief Scientific Officer
Period of report
Mar 7, 2019
Accepted (ET)
Mar 8, 2019 · 5:51 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001446847
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common StockF2 | Mar 7, 2019 | S | 225,500 | $13.29 | D | 577,980 | D | |
| Class A Common StockF3 | Mar 8, 2019 | S | 49,500 | $13.15 | D | 528,480 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Mark Currie sold the shares of common stock of Ironwood Pharmaceuticals, Inc. to raise proceeds to fund a portion of his commitment to purchase shares of common stock of Cyclerion Therapeutics, Inc. alongside other investors in a private placement.
- F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.94 to $13.45, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F3The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.04 to $13.39, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.